[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Get Your Money Out of U.S. Banks Immediately]( Wall Street legend is urging Americans to prepare for a historic financial reset in 2023. Get out of cash and into a new vehicle 50 years in the making. --------------------------------------------------------------- December 20, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers across all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- Sponsor Message [New Documentary: The Two Men Destroying America]( This is causing a lot of controversy… It’s a new documentary called [The Two Men Destroying America.]( And a lot of powerful people would rather this exposé never saw the light of day. Chances are, they’ll attempt to have it scrubbed from existence. That’s because it tells the true (and terrifying) story of how two men from New York have engineered a reset of not just your personal wealth, but the entire US economic system. [Click play to watch The Two Men Destroying America]( --------------------------------------------------------------- [Viking Therapeutics, VKTX]( Recent Analyst Action: Naz Rahman, analyst at Maxim Group, reiterates coverage on [Viking Therapeutics (VKTX)](in the Healthcare sector with a Buy rating and a price target of $15.00 (1 day ago). - Recent Price: $6.77 - Average Analyst Price Target: $13.80 (103.84%) - Market Cap: $536.05M [TipRanks.com]( also reports that [Viking Therapeutics](currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $13.80. The target pricing ranges from a high forecast of $21.00 down to a low forecast of $10.00. [Viking Therapeutics (VKTX)](’s last closing price was $6.77 which would put the average price target at $13.80. Here are 3rd party ratings for [VKTX](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 23% (56 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [3 Billionaires Have Already Invested in My No. 1 Fear-to-Fortune Stock]( Billionaires are taking advantage of market turmoil by investing heavily into my favorite “fear-to-fortune” stock. It’s a secret used by investors like Warren Buffett, David Tepper and Sir John Templeton to become filthy rich. [How it works is simple…]( --------------------------------------------------------------- [Calithera Bio, CALA]( Recent Analyst Action: Aydin Huseynov, analyst at Ladenburg Thalmann & Co., reiterates coverage on [Calithera Bio (CALA)](in the Healthcare sector with a Hold rating (1 month ago). - Recent Price: $2.5 - Average Analyst Price Target: $5.00 (100.00%) - Market Cap: $11.73M [TipRanks.com]( also reports that [Calithera Bio](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $5.00. The target pricing ranges from a high forecast of $8.00 down to a low forecast of $2.00. [Calithera Bio (CALA)](’s last closing price was $2.5 which would put the average price target at $5.00. Here are 3rd party ratings for [CALA](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 36% (89 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [TAL Education Group, TAL]( Recent Analyst Action: Felix Liu, analyst at UBS, reiterates coverage on [TAL Education Group (TAL)](in the Services sector with a Buy rating and a price target of $6.5 (1 month ago). - Recent Price: $8.66 - Average Analyst Price Target: $5.73 (-33.83%) - Market Cap: $4.04B [TipRanks.com]( also reports that [TAL Education Group](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $5.73. The target pricing ranges from a high forecast of $6.50 down to a low forecast of $4.70. [TAL Education Group (TAL)](’s last closing price was $8.66 which would put the average price target at $5.73. Here are 3rd party ratings for [TAL](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 34% (84 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Performant Financial, PFMT]( Recent Analyst Action: Kyle Bauser, analyst at Lake Street, reiterates coverage on [Performant Financial (PFMT)](in the Services sector with a Buy rating and a price target of $8.00 (1 month ago). - Recent Price: $2.82 - Average Analyst Price Target: $8.00 (183.69%) - Market Cap: $205.75M [TipRanks.com]( also reports that [Performant Financial](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.00 . The target pricing ranges from a high forecast of $8.00 down to a low forecast of $8.00. [Performant Financial (PFMT)](’s last closing price was $2.82 which would put the average price target at $8.00. Here are 3rd party ratings for [PFMT](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: n/a, n/a [Click here for chart >>]( -------------------------------------------------------------------------- [Mammoth Energy Services, TUSK]( Recent Analyst Action: Unknown Analyst, analyst at Singular, reiterates coverage on [Mammoth Energy Services (TUSK)](in the Industrial Goods sector with a Buy rating and a price target of $10.5 (2 weeks ago). - Recent Price: $7.58 - Average Analyst Price Target: $10.50 (38.52%) - Market Cap: $338.76M [TipRanks.com]( also reports that [Mammoth Energy Services](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.50. The target pricing ranges from a high forecast of $10.50 down to a low forecast of $10.50. [Mammoth Energy Services (TUSK)](’s last closing price was $7.58 which would put the average price target at $10.50. Here are 3rd party ratings for [TUSK](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: n/a, n/a [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [URGENT: Tesla ALERT]( Tesla just keeps blasting HIGHER. It’s why [this trader is now convinced]( we’re at the BEGINNING of another epic rally. He called Tesla at $113… and now he’s predicting another explosive run. [Go here to see what he’s telling everyone to do right now.]( If you wait until tomorrow, it might be too late. --------------------------------------------------------------- [Cytokinetics, CYTK]( Recent Analyst Action: Srikripa Devarakonda, analyst at Truist Financial, reiterates coverage on [Cytokinetics (CYTK)](in the Healthcare sector with a Buy rating and a price target of $60.00 (10 hours ago). - Recent Price: $45.02 - Average Analyst Price Target: $63.36 (40.74%) - Market Cap: $4.17B [TipRanks.com]( also reports that [Cytokinetics](currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $63.36. The target pricing ranges from a high forecast of $80.00 down to a low forecast of $47.00. [Cytokinetics (CYTK)](’s last closing price was $45.02 which would put the average price target at $63.36. Here are 3rd party ratings for [CYTK](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 23% (56 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [Zymeworks, ZYME]( Recent Analyst Action: Akash Tewari, analyst at Jefferies, reiterates coverage on [Zymeworks (ZYME)](in the Healthcare sector with a Buy rating and a price target of $11.00 (1 day ago). - Recent Price: $6.98 - Average Analyst Price Target: $11.00 (57.59%) - Market Cap: $427.74M [TipRanks.com]( also reports that [Zymeworks](currently has 6 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $11.00. The target pricing ranges from a high forecast of $18.00 down to a low forecast of $7.00. [Zymeworks (ZYME)](’s last closing price was $6.98 which would put the average price target at $11.00. Here are 3rd party ratings for [ZYME](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 23% (56 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message Friends… On October 27, the CEO of New England’s largest energy company sent a desperate letter to the White House. ["This represents a serious public health and safety threat,"](Eversource CEO Joe Nolan wrote in a letter to President Joe Biden. He then begged Joe Biden to use the federal government's emergency powers to make sure natural gas will be available in New England this winter. There’s only one problem. There’s nothing Biden or anyone can do at this point. All available natural gas is on its way to Europe. When large parts of New England go dark and freeze this winter, a lot of people will call it a shocking natural disaster. Or they’ll say it was because Russia invaded Ukraine. But cities don’t go dark and freeze in the wealthiest country in the world by accident. My name is Porter Stansberry. I’m the founder of one of the world’s largest financial research firms. I’ve spent the last two years researching this coming crisis. I’ve been writing about it in my newsletter, The Big Secret on Wall Street, since June… And now that this crisis is set to unfold, exactly the way I’ve been predicting, I’ve uploaded an eye-opening video that tells the whole sordid tale. I name names in it. And I reveal who caused this crisis, and why… Do yourself a favor. Before it’s taken offline – which could happen at any time – check out this [shocking video](. I’ve seen in the past just how far powerful people will go to silence me. Don’t miss this: [CLICK HERE.]( --------------------------------------------------------------- And there you have it--7 Five Day Gainers across all US Exchanges. Sincerely, The Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software